A Study of the Safety and Efficacy of EBV Specific T-cell Lines

NCT02580539 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Epstein-Barr Virus Infections
Post-Transplant Lymphoproliferative Disorder
Lymphoma

Interventions

BIOLOGICAL: Group A
BIOLOGICAL: Group B

Sponsor

Dr. Jean-Sebastien Delisle, MD, PhD